Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05193305

Study of Healthy Cohort for Early Detection of Cancer

Cancer produces a significant burden on society with a majority diagnosed at late stages when the chance of cure is low. Early diagnosis improves patient outcomes. Data consisting of lifestyle factors, medications, physical activity, years before conventional cancer diagnosis is also worthwhile for to determine early detection. This is only achievable with longitudinal tracking of a large number of healthy individuals and identifying those who do develop cancer over time.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Healthy

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Johns Hopkins Hospital

Baltimore, Maryland, 21205, United States

Location status: Recruiting

Location contact

Elham Afghani, MD

CONTACT

About this study

To conduct a longitudinal cohort study of patients who do not have a malignancy at the time of enrollment and are followed over a 20 year period to see if patients develop a malignancy and associate clinical and lifestyle factors as well as collection of blood. All adults 18 years of age and older undergoing upper or lower endoscopy for routine medical care will be eligible for this study.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All adults 18 years of age of older undergoing upper or lower endoscopy for routine medical care.

Exclusion criteria

  • Persons with current malignancy
  • Persons with history of malignancy and treatment within last 5 years of enrollment, excluding non-melanoma skin cancer or cervical in-situ.
  • Persons who are unable or unwilling to provide repeat blood samples and complete follow-up questionnaires
  • Persons who lack the capacity to provide consent
  • Persons who do not speak English
  • Persons who are visually or hearing impaired.

Treatment and study plan

Primary outcomes

  1. Development of malignancy

    Time frame: Up to 20 years

    Assessment of participants for the development of malignancy during a 20-year follow-up period.

Secondary outcomes

  1. Development of biomarkers

    Time frame: Up to 20 years

    To identify proteins, RNA and DNA that have changes in expression in those who develop cancer.

Study contacts

Contact information is provided by the study sponsor or research team.

Elham Afghani

CONTACT

[email protected]

410-955-5000

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Important dates

Study start
2023
Primary completion
2028
Study completion
2043
First posted
Jan 14, 2022
Registry last updated
Feb 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.